Revolutionizing Medicine: Targeted Protein Degradation Market to Skyrocket to $247.5 Billion by 2030

The Targeted Protein Degradation Market was valued USD 113.8 Billion in 2022 and projected to reach USD 247.5 Billion by 2030, growing at a CAGR of 10.2% during the forecast period of 2023-2030.

The targeted protein degradation market is a rapidly evolving sector within the pharmaceutical industry that is revolutionizing drug development and therapeutic interventions. Here is a comprehensive content overview, highlighting key points, key trends, and recent industry news.

Download a Free sample copy of Report:https://www.marketdigits.com/request/sample/3825

Major vendors in the global Targeted Protein Degradation market are Arvinas, Inc., Bayer AG, C4 Therapeutics, Inc., Cellestia Biotech AG, Cullgen Inc., Cyrus Biotechnology, Inc., Daiichi Sankyo Co., Ltd., Kymera Therapeutics, Inc., Mirati Therapeutics, Inc., Nurix Therapeutics, Inc., Peptidream Inc., Progenra Inc., Proteolix, Inc., Sanofi S.A., Shield Therapeutics, Inc., Syros Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Vivace Therapeutics, Inc., Xencor, Inc., Zenith Epigenetics Ltd. and Others.

Key Points:

Segment Analysis: The market is segmented based on types of targeted protein degradation technologies, including Degronimids, PROTACs, IMiDs, and others, catering to therapeutic areas like inflammatory disorders, neurological disorders, and oncological disorders.

Major Players: Key companies operating in the targeted protein degradation market include Eli Lilly and Company, Gilead Sciences, Novartis AG, Pfizer Inc., and others, contributing to the market's growth through research, development, and product launches.

Market Drivers: Factors driving market growth include the increasing demand for sustainable and environmentally friendly products, the potential of targeted protein degradation in developing effective therapies, and the broad applicability of this approach in targeting disease-causing proteins.

Read More:https://www.marketdigits.com/targeted-protein-degradation-market-1705393450

Major Segmentations Are Distributed as follows:

By Technology
PROTACs (Proteolysis-Targeting Chimeras)
LYTACs (Lysosome-Targeting Chimeras)
SNIPERs (Specific and Non-genetic IAP-dependent Protein ERasers),
Molecular glues
Others

By Therapeutic Area
Neurological Disorders
Oncological Disorders
Others

By Route of administration
Oral
Intravenous
Others

By Region

North America
US
Canada

Latin America
Brazil
Mexico
Argentina
Colombia
Chile
Peru
Rest of Latin America

Europe
UK
Germany
France
Italy
Spain
Russia
BENELUX
CIS & Russia
Nordics
Austria
Poland
Rest of Europe

Asia Pacific
China
Japan
India
South Korea
Thailand
Indonesia
Malaysia
Vietnam
Australia & New Zealand
Rest of Asia Pacific

Rest of the World
Saudi Arabia
UAE
South Africa
Nigeria
Egypt
Israel
Turkey

Recent Developments

October 2023: AbbVie announced collaboration with C4 Therapeutics to develop and commercialize next-generation TPD therapies for cancer and other diseases.

August 2023, Novartis entered into a strategic partnership with Arvinas to develop and commercialize TPD therapies for multiple disease areas.

September 2023, Presented data on preclinical TPD candidates for Parkinson's disease and Alzheimer's disease at the Society for Neuroscience meeting.
Key Trends:

Exponential Growth: The targeted protein degradation market is set to experience exponential growth by 2031, driven by various factors that are increasing the demand for innovative therapeutic interventions.

Sustainability Focus: A prominent trend in the market is the rising demand for sustainable and environmentally friendly products, aligning with the global shift towards eco-friendly practices and products.

Competitive Landscape: The market is witnessing intensified competition due to the entry of new players, ranging from startups to large pharmaceutical companies, all aiming to leverage the potential of targeted protein degradation for developing effective therapies.

Recent Industry News:

Market Size Expansion: The targeted protein degradation market size was valued at USD 400.5 million in 2021 and is expected to grow to USD 3,300.0 million by 2031, indicating a significant growth trajectory and market potential.

Innovative Drug Development: Targeted protein degradation is considered an innovative pharmacological concept that offers practical drug development opportunities, heralding a new paradigm in therapeutic interventions by targeting specific proteins with high selectivity and oral bioavailability.

Increased Research and Development: With growing investments in research and development activities, more companies are entering the market to offer their services, leading to an intensified competitive landscape and a surge in developments compatible with targeted protein degradation.

Get this report at a discount:https://www.marketdigits.com/request/discount/3825

In conclusion, the targeted protein degradation market is witnessing substantial growth and innovation, driven by the increasing demand for effective and sustainable therapeutic solutions. Key players, market trends, and recent industry news collectively indicate a promising future for this sector, with a focus on developing advanced therapies and addressing unmet medical needs.

Contact Us:

1248 CarMia Way Richmond,
VA 23235, United States.
Phone: +1 510-730-3200
Email: sales@marketdigits.com
Website: https://www.marketdigits.com

About MarketDigits:

MarketDigits is one of the leading business research and consulting companies that helps clients to tap new and emerging opportunities and revenue areas, thereby assisting them in operational and strategic decision-making. We at MarketDigits believe that a market is a small place and an interface between the supplier and the consumer, thus our focus remains mainly on business research that includes the entire value chain and not only the markets.

We offer services that are most relevant and beneficial to the users, which help businesses to sustain themselves in this competitive market. Our detailed and in-depth analysis of the markets catering to strategic, tactical, and operational data analysis & reporting needs of various industries utilize advanced technology so that our clients get better insights into the markets and identify lucrative opportunities and areas of incremental revenues.

This release was published on openPR.